The Toronto Cannabis and Cannabinoid Research Consortium brings together researchers and trainees who are actively engaged in research on cannabis and cannabinoids at the University of Toronto and Toronto Academic Health Sciences Network
TC3 is a tri-campus, multi-institution, interdisciplinary Institutional Strategic Initiative at the University of Toronto
​
Situated at the heart of Canada’s medical research and innovation ecosystem, TC3 has the unique depth and breadth of expertise and the capacity to address almost every crucial and pressing research question related to cannabis and cannabinoids and to translate research findings into real world solutions for society
TC3 is pioneering transformative cannabis and cannabinoid research and training approaches at the convergence of disciplines
The TC3 is led by an interdisciplinary team of researchers from
3 University of Toronto campuses, 6 faculties, 11 departments and 3 hospital and research institutes
MEMBER SPOTLIGHT
My research focuses on psychosocial aspects of cannabis use and treatment. Several of my graduate students are conducting research on cannabis use. Current projects in our lab involve:
​
​
-
examining parent-child relationships and impact on risk and well-being in emerging adulthood, including cannabis use
-
qualitative research on cannabis use within the context of emerging adult development
-
facets of emotion regulation and cannabis use in emerging adulthood
Dr. Abby Goldstein
Ontario Institute
for Studies on Education
University of Toronto
TRAINEE SPOTLIGHT
Yalin studies neuroinflammatory mechanisms mediated by glial cells in non-human primate, rat, and cell culture models to understand how adolescent cannabis exposure might lead to adverse psychiatric outcomes and identify potential therapeutic targets.
Yalin Sun
Lab of Dr. Susan R. George
University of Toronto
ALUMNI SPOTLIGHT
Alexandra Santos is currently working at BlueRock Therapeutics as a Senior Research Associate on the Analytical and Quality Control team. The company focuses on developing stem cell therapy products, and the primary product she supports is a treatment for Parkinson’s Disease, which is presently in clinical trials.
​
In her role, she develops various assays and characterizes the drug product to ensure it meets the stringent quality standards required for continued advancement in the clinical pipeline.
Alexandra Santos
BlueRock Therapeutics
FUNDERS & PARTNERS
